Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVSENSI: Immunosuppression in Late Renal Graft Failure
NCT06676696Phase 4Recruiting
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Peptides, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus and cyclosporine in Human Leukocyte Antigen Sensitization (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Degree of HLA sensitization at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
tacrolimuscyclosporine
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT06676696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676696.